HHS partners with GSK on antibiotics for superbugs

05/22/2013 | Reuters · Bloomberg

GlaxoSmithKline will work in partnership with HHS' Biomedical Advanced Research and Development Authority to develop new antibiotics for drug-resistant pathogens and diseases that could be used as weapons. GSK will receive $40 million initially and up to $200 million if the deal is renewed.

View Full Article in:

Reuters · Bloomberg

Published in Briefs: